National Commission on Marihuana and Drug Abuse

National Commission on Marihuana and Drug Abuse
Name	National Commission on Marihuana and Drug Abuse
Formed	1970
Dissolved	1973
Jurisdiction	United States
Headquarters	Washington, D.C.
Parent agency	United States Federal Government
Chair	Raymond P. Shafer
Members	See membership

National Commission on Marihuana and Drug Abuse The National Commission on Marihuana and Drug Abuse was a presidentially appointed panel convened to study marijuana and related drug abuse issues in the United States during the administration of Richard Nixon. It produced a landmark 1972 report recommending major reforms to criminal penalties and public health approaches, influencing debates in the United States Congress, state legislatures, and advocacy groups such as the American Civil Liberties Union and the National Organization for the Reform of Marijuana Laws. The commission's findings intersected with contemporaneous policy discussions involving figures from the Department of Justice, the White House, and academic institutions including Harvard University and the Johns Hopkins University.

Background and Establishment

The commission was established by Executive Order 11572 in 1970 by President Richard Nixon following public debate spurred by cultural shifts associated with the 1960s counterculture, the Vietnam War, and high-profile cases in cities like New York City and Los Angeles. Calls for study came from elected officials including members of the United States Senate and the United States House of Representatives who had clashed with law enforcement agencies such as the Federal Bureau of Investigation and the Drug Enforcement Administration over enforcement priorities. Prominent legal developments such as rulings from the Supreme Court of the United States and legislative actions in states like California (later Proposition 215) shaped the political context that prompted the commission's mandate to assess medical, social, and legal aspects tied to narcotics policy.

Membership and Organization

The commission was chaired by former Pennsylvania Governor Raymond P. Shafer and included appointees from diverse backgrounds: academics from Columbia University and Yale University, legal experts formerly associated with the Department of Justice and the American Bar Association, medical researchers affiliated with University of California, San Francisco and Massachusetts General Hospital, and civic leaders from organizations such as the National Governors Association and the National League of Cities. Members convened in public hearings attended by representatives of advocacy groups like Common Sense for Drug Policy and opponents including the Mothers Against Drunk Driving-era activists. Administrative support came from staff linked to the Office of Management and Budget and the General Services Administration.

Research Methods and Activities

The commission employed interdisciplinary methods drawing on epidemiological studies from institutions such as the National Institutes of Health, sociological surveys influenced by work at the University of Michigan, and criminal justice data compiled by the Bureau of Justice Statistics. It held public hearings in cities including Chicago, San Francisco, and Miami, subpoenaed witnesses from the Central Intelligence Agency and the National Institute on Drug Abuse, and reviewed international models from countries like the Netherlands and Switzerland. The commission commissioned laboratory studies referencing protocols used at Johns Hopkins Hospital and consulted policy analyses from think tanks such as the Brookings Institution and the Heritage Foundation. Quantitative analyses drew on datasets comparable to those maintained by the Census Bureau and the National Center for Health Statistics.

The Shafer Commission Report (1972)

The 1972 report, commonly called the Shafer Report, concluded that marijuana was not as harmful as classified under existing federal statutes and recommended decriminalization of personal possession in many cases, favoring treatment over incarceration. The report referenced medical literature from journals like the New England Journal of Medicine and the Journal of the American Medical Association, and cited comparative legal frameworks in Portugal and the United Kingdom. It recommended changes to the Controlled Substances Act implementation and influenced legislative proposals introduced by members of the United States Congress such as reform bills debated by the Senate Judiciary Committee. The report’s executive summary was debated in hearings featuring testimony from physicians associated with Mayo Clinic and psychologists from Stanford University.

Reception, Controversy, and Political Impact

The report provoked immediate reactions from political figures including President Richard Nixon, Attorney General John Mitchell, and members of the Congressional Black Caucus, and was criticized by law enforcement organizations such as the International Association of Chiefs of Police. Civil liberties advocates from the American Civil Liberties Union and reform groups like the National Organization for the Reform of Marijuana Laws praised its recommendations, while conservative commentators at outlets associated with publishers like Hearst Corporation and networks such as ABC denounced it. State-level responses varied: lawmakers in Oregon, Colorado, and New York (state) considered legislation influenced by the report; enforcement agencies in jurisdictions including Texas and Florida resisted change. The Nixon administration publicly dismissed parts of the commission's recommendations, and political operatives connected to the Committee to Re-elect the President and campaign strategists in the Republican National Committee leveraged the controversy in electoral messaging.

Legacy and Influence on Drug Policy

Despite initial political resistance, the commission’s conclusions informed later developments including legislative reforms in several states, university drug policy revisions at institutions such as University of California, Berkeley and Columbia University, and international shifts toward harm-reduction policies in cities like Amsterdam. The report influenced subsequent federal commissions and advisors, including panels convened under Presidents Jimmy Carter and Bill Clinton, and shaped advocacy by organizations such as the Drug Policy Alliance and the RAND Corporation policy researchers. Its emphasis on public health over punitive measures presaged policy experiments in Portugal and municipal decriminalization in places such as Seattle and Denver.

Subsequent Evaluations and Historical Assessments

Historians and policy analysts from institutions like Princeton University and Georgetown University have revisited the commission’s work in light of later scientific evidence on cannabinoids published by researchers at Brown University and Scripps Research. Retrospectives in journals associated with Oxford University Press and policy reviews by the Urban Institute have assessed the report’s accuracy and long-term impact on incarceration rates tracked by the Bureau of Justice Statistics. Contemporary debates about legalization initiatives, tax frameworks debated in state legislatures and Supreme Court cases related to drug policy continue to cite the Shafer Report as a critical early federal assessment influencing the evolution of United States drug policy.

Category:Drug policy in the United States